ARTICLE | Product Development
Deferred differentiation in migraine
How the anti-CGRP reimbursement landscape could shape in the near and long term
September 29, 2018 3:46 AM UTC
The best hope for CGRP antagonists to differentiate themselves lies in data that aren’t yet available. In the meantime, the makers of the migraine therapies will likely have to trade discounts on their already reasonable prices for favorable formulary status.
After decades of little progress in treating migraines, and only a handful of repurposed drugs to prevent it, on May 17, Amgen Inc.’s Aimovig erenumab-aooe became the first drug ever approved that was expressly developed to prevent the condition. ...